Abstract: Embodiments of the present invention are drawn to pure forms of human or simian immunodeficiency virus trimeric gp120/gp41 Env protein (Env trimers) and methods for making them. These embodiments address the need for an authentic immunogen lacking uncleaved gp160 Env protein and/or other forms of Env, such as gp41 “stumps” dissociated from gp120, which interfere with neutralizing antibody production in a vaccinated subject.

Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

Abstract: This invention provides stable HIV-1 pre-fusion envelope glycoprotein trimeric complexes. This invention also provides related polypeptides and compositions comprising pharmaceutically acceptable particles and the trimeric complexes operably affixed thereto. This invention further provides related nucleic acids, vectors, host cells, compositions, production methods, and prophylactic and therapeutic methods.